Subscribe to RSS
Efficacy, Retention Rate, and Influencing Factors of Ketogenic Diet Therapy in Children with Refractory Epilepsy: A Retrospective StudyFunding This study was supported by a Grant from the Zhejiang Provincial Education Department Foundation of China (Y201737746).
Background This study aimed to evaluate the efficacy and retention rate of a ketogenic diet (KD) and assess factors that influence the efficacy of KD therapy in children with refractory epilepsy (RE).
Methods We retrospectively studied the efficacy and retention rate of 56 RE children who accepted KD therapy from January 2013 to December 2019. Patients who had a ≥50% reduction in seizure frequency were defined as responders. The retention rate was calculated as the proportion of children who continued KD/the total number of children who were followed up at the time of enrollment. We also analyzed the effects of different factors (such as gender, KD initial age, KD duration, the type of epilepsy syndrome, and others) on the efficacy of the KD.
Results (1) The efficacy rates for the KD at 3, 6, 12, and 18 months were 51.8, 53.6, 39.2, and 23.2%, respectively. (2) The retention rates for the KD at 3, 6, 12 and 18 months were 100, 69.6, 41.1, and 23.2%, respectively. (3) There was no correlation between efficacy and gender, epilepsy onset age, the type of epilepsy syndrome, electroencephalogram improvement, or the number of antiseizure medications, while cranial magnetic resonance imaging (MRI) abnormalities, KD duration, and KD initial age affected its efficacy at 3 months.
Conclusion (1) KD therapy for refractory childhood epilepsy was effective and produced a high retention rate. (2) MRI abnormalities and the initial age and duration of KD influenced its short-term efficacy in RE children.
Received: 25 April 2022
Accepted: 08 September 2022
Accepted Manuscript online:
13 September 2022
Article published online:
21 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Kwan P, Arzimanoglou A, Berg AT. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 2010; 51 (06) 1069-1077
- 2 Garcia-Penas JJ. Epilepsy, cognition and ketogenic diet. Rev Neurol 2018; 66 (S01): S71-S75
- 3 Sourbron J, Klinkenberg S, van Kuijk SMJ. et al. Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis. Childs Nerv Syst 2020; 36 (06) 1099-1109
- 4 Pizzo F, Collotta AD, Di Nora A, Costanza G, Ruggieri M, Falsaperla R. Ketogenic diet in pediatric seizures: a randomized controlled trial review and meta-analysis. Expert Rev Neurother 2022; 22 (02) 169-177
- 5 Lambrechts DA, de Kinderen RJ, Vles JS, de Louw AJ, Aldenkamp AP, Majoie HJ. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand 2017; 135 (02) 231-239
- 6 Wibisono C, Rowe N, Beavis E. et al. Ten-year single-center experience of the ketogenic diet: factors influencing efficacy, tolerability, and compliance. J Pediatr 2015; 166 (04) 1030-6.e1
- 7 van der Louw E, van den Hurk D, Neal E. et al. Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol 2016; 20 (06) 798-809
- 8 Bjurulf B, Magnus P, Hallböök T, Strømme P. Potassium citrate and metabolic acidosis in children with epilepsy on the ketogenic diet: a prospective controlled study. Dev Med Child Neurol 2020; 62 (01) 57-61
- 9 Wells J, Swaminathan A, Paseka J, Hanson C. Efficacy and safety of a ketogenic diet in children and adolescents with refractory epilepsy-a review. Nutrients 2020; 12 (06) 1809
- 10 Winczewska-Wiktor A, Hirschfeld AS, Badura-Stronka M, Komasińska-Piotrowska P, Steinborn B. Analysis of factors that may affect the effectiveness of ketogenic diet treatment in pediatric and adolescent patients. J Clin Med 2022; 11 (03) 606
- 11 Alameen Ali H, Muthaffar O, AlKarim N. et al. The efficacy of non-fasting ketogenic diet protocol in the management of intractable epilepsy in pediatric patients: a single center study from Saudi Arabia. J Int Med Res 2022; 50 (03) 300060 5221081714
- 12 Cai QY, Zhou ZJ, Luo R. et al. Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies. World J Pediatr 2017; 13 (06) 528-536
- 13 Sariego-Jamardo A, García-Cazorla A, Artuch R. et al. Efficacy of the ketogenic diet for the treatment of refractory childhood epilepsy: cerebrospinal fluid neurotransmitters and amino acid levels. Pediatr Neurol 2015; 53 (05) 422-426
- 14 Li H, Ouyang M, Zhang P, Fei L, Hu X. The efficacy and safety of a ketogenic diet for children with refractory epilepsy in China: a retrospective single-center cohort study. Transl Pediatr 2020; 9 (04) 561-566
- 15 Riantarini I, Kim HD, Ko A. et al. Short- and long-term seizure-free outcomes of dietary treatment in infants according to etiology. Seizure 2019; 71: 100-104
- 16 Baby N, Vinayan KP, Pavithran N, Grace Roy A. A pragmatic study on efficacy, tolerability and long term acceptance of ketogenic diet therapy in 74 South Indian children with pharmacoresistant epilepsy. Seizure 2018; 58: 41-46
- 17 Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev 2020; 6 (06) CD001903
- 18 Feng L, Wang J, Li X, Hu Y, Hong S, Jiang L. Prospective control study of efficacy and influencing factors of a ketogenic diet on refractory epilepsy in children. Transl Pediatr 2022; 11 (01) 138-148
- 19 Song JM, Hahn J, Kim SH, Chang MJ. Efficacy of treatments for infantile spasms: a systematic review. Clin Neuropharmacol 2017; 40 (02) 63-84
- 20 Winesett SP, Bessone SK, Kossoff EH. The ketogenic diet in pharmacoresistant childhood epilepsy. Expert Rev Neurother 2015; 15 (06) 621-628
- 21 Palmer S, Towne MC, Pearl PL. et al. SLC6A1 mutation and ketogenic diet in epilepsy with myoclonic-atonic seizures. Pediatr Neurol 2016; 64: 77-79
- 22 Dressler A, Trimmel-Schwahofer P, Reithofer E. et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - comparison with various standard antiepileptic drug regimen. Epilepsy Res 2015; 109: 81-89
- 23 Hirano Y, Oguni H, Shiota M, Nishikawa A, Osawa M. Ketogenic diet therapy can improve ACTH-resistant West syndrome in Japan. Brain Dev 2015; 37 (01) 18-22
- 24 Vehmeijer FO, van der Louw EJ, Arts WF, Catsman-Berrevoets CE, Neuteboom RF. Can we predict efficacy of the ketogenic diet in children with refractory epilepsy?. Eur J Paediatr Neurol 2015; 19 (06) 701-705
- 25 Pires ME, Ilea A, Bourel E. et al. Ketogenic diet for infantile spasms refractory to first-line treatments: an open prospective study. Epilepsy Res 2013; 105 (1-2): 189-194
- 26 Kang HC, Lee YJ, Lee JS. et al. Comparison of short- versus long-term ketogenic diet for intractable infantile spasms. Epilepsia 2011; 52 (04) 781-787
- 27 Kossoff EH, Zupec-Kania BA, Auvin S. et al; Charlie Foundation, Matthew's Friends, Practice Committee of the Child Neurology Society. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open 2018; 3 (02) 175-192
- 28 Lemmon ME, Terao NN, Ng YT, Reisig W, Rubenstein JE, Kossoff EH. Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature. Dev Med Child Neurol 2012; 54 (05) 464-468
- 29 Thammongkol S, Vears DF, Bicknell-Royle J. et al. Efficacy of the ketogenic diet: which epilepsies respond?. Epilepsia 2012; 53 (03) e55-e59
- 30 Schubert-Bast S, Strzelczyk A. Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Ther Adv Neurol Disord 2021; 14: 1756286 4211031100
- 31 Kang JW, Rhie SK, Yu R. et al. Seizure outcome of infantile spasms with focal cortical dysplasia. Brain Dev 2013; 35 (08) 816-820